The value of surgery in the patients with <italic style="font-style: italic">de novo</italic> stage Ⅳ breast cancer

Luyan CHEN; Lixue WANG; Peifen FU

doi:10.19401/j.cnki.1007-3639.2023.05.002

您当前的位置：

首页 >

文章列表页 >

The value of surgery in the patients with de novo stage Ⅳ breast cancer

Specialists' Commentary | 更新时间：2025-12-31

- The value of surgery in the patients with de novo stage Ⅳ breast cancer
- China Oncology Vol. 33, Issue 5, Pages: 431-436(2023)
- 作者机构：
  
  浙江大学医学院附属第一医院乳腺外科，浙江杭州 310009
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.05.002
  CLC： R737.9
- Received：31 January 2023，
  
  Revised：2023-05-04，
  
  Published：30 May 2023
- 稿件说明：
移动端阅览
Luyan CHEN, Lixue WANG, Peifen FU. The value of surgery in the patients with de novo stage Ⅳ breast cancer[J]. China Oncology, 2023, 33(5): 431-436.
DOI：

Luyan CHEN, Lixue WANG, Peifen FU. The value of surgery in the patients with de novo stage Ⅳ breast cancer[J]. China Oncology, 2023, 33(5): 431-436. DOI： 10.19401/j.cnki.1007-3639.2023.05.002.

摘要

乳腺癌是全世界常见的恶性肿瘤之一，其中约6%的患者为新发Ⅳ期乳腺癌，是不可治愈的。传统意义上外科手术的作用仅限于缓解患者症状，改善生活质量，降低肿瘤负荷。随着全身治疗手段的进步，通过多学科团队制订综合治疗方案，仅有寡转移灶的Ⅳ期乳腺癌患者往往能获得长期生存，而原发灶及转移灶的R0切除可以延长无进展生存期（progression-free survival，PFS），可能会带来生存获益，因此是否需要行乳腺癌原发灶及转移灶的手术治疗成为临床热点，并存在较大争议。本文对新发Ⅳ期乳腺癌患者的手术价值进行深入探讨。

Abstract

Breast cancer is one of the common malignant tumors in the world. About 6% of the patients are

de novo

stage Ⅳ breast cancer

which is incurable. Traditionally

the role of surgery has been confined to relieving symptoms

improving quality of life and reducing tumor load. Nowadays

a multidisciplinary team is a prerequisite for optimal management

and patients with oligometastatic lesion always live for a long time. R0 resection of the primary and metastatic foci can extend the time of progression-free survival (PFS)

which may bring survival benefits. Therefore

whether to perform surgery has become a hot clinical issue. This article deeply discussed extensively the surgical value in

de novo

stage Ⅳ breast cancer patients.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.v71.3 http://doi.org/10.3322/caac.v71.3 https://onlinelibrary.wiley.com/toc/15424863/71/3 https://onlinelibrary.wiley.com/toc/15424863/71/3

GIAQUINTO A N , SUNG H , MILLER K D , et al . Breast cancer statistics, 2022 [J ] . CA A Cancer J Clin , 2022 , 72 ( 6 ): 524 - 541 . DOI: 10.3322/caac.v72.6 http://doi.org/10.3322/caac.v72.6 https://onlinelibrary.wiley.com/toc/15424863/72/6 https://onlinelibrary.wiley.com/toc/15424863/72/6

SIEGEL R L , MILLER K D , JEMAL A . Cancer statistics, 2015 [J ] . CA A Cancer J Clin , 2015 , 65 ( 1 ): 5 - 29 . DOI: 10.3322/caac.21254 http://doi.org/10.3322/caac.21254 http://doi.wiley.com/10.3322/caac.21254 http://doi.wiley.com/10.3322/caac.21254

ZHENG R S , ZHANG S W , ZENG H M , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Center , 2022 , 2 ( 1 ): 1 - 9 . DOI: 10.1016/j.jncc.2022.02.002 http://doi.org/10.1016/j.jncc.2022.02.002 https://linkinghub.elsevier.com/retrieve/pii/S2667005422000047 https://linkinghub.elsevier.com/retrieve/pii/S2667005422000047

ARCIERO C , LIU Y , GILLESPIE T , et al . Surgery and survival in patients with stage Ⅳ breast cancer [J ] . Breast J , 2019 , 25 ( 4 ): 644 - 653 . DOI: 10.1111/tbj.2019.25.issue-4 http://doi.org/10.1111/tbj.2019.25.issue-4 https://onlinelibrary.wiley.com/toc/15244741/25/4 https://onlinelibrary.wiley.com/toc/15244741/25/4

ZHENG A , GUO B L , ZHANG J G , et al . Clinical information and management status of de novo stage Ⅳ breast cancer patients: a Chinese multicenter investigation (CSBrS-002) [J ] . Chin Med J (Engl) , 2021 , 134 ( 13 ): 1569 - 1575 .

MALINOWSKI C , LEI X D , ZHAO H , et al . Association of Medicaid expansion with mortality disparity by race and ethnicity among patients with de novo stage Ⅳ breast cancer [J ] . JAMA Oncol , 2022 , 8 ( 6 ): 863 - 870 . DOI: 10.1001/jamaoncol.2022.0159 http://doi.org/10.1001/jamaoncol.2022.0159 https://jamanetwork.com/journals/jamaoncology/fullarticle/2790997 https://jamanetwork.com/journals/jamaoncology/fullarticle/2790997

MALMGREN J A , MAYER M , ATWOOD M K , et al . Differential presentation and survival of de novo and recurrent metastatic breast cancer over time : 1990-2010[J ] . Breast Cancer Res Treat , 2018 , 167 ( 2 ): 579 - 590 . DOI: 10.1007/s10549-017-4529-5 http://doi.org/10.1007/s10549-017-4529-5 http://link.springer.com/10.1007/s10549-017-4529-5 http://link.springer.com/10.1007/s10549-017-4529-5

GRADISHAR W J , MORAN M S , ABRAHAM J , et al . Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw , 2022 , 20 ( 6 ): 691 - 722 . DOI: 10.6004/jnccn.2022.0030 http://doi.org/10.6004/jnccn.2022.0030 https://jnccn.org/view/journals/jnccn/20/6/article-p691.xml https://jnccn.org/view/journals/jnccn/20/6/article-p691.xml

中华医学会外科学分会 . 乳腺外科临床实践指南(2022版) [M ] . 人民卫生出版社 , 2022 .

Surgery Branch of Chinese Medical Association . Practice guidelines of Chinese society of breast surgery (2022) [M ] . People’s Medical Publishing House , 2022 .

GENNARI A , ANDRÉ F , BARRIOS C H , et al . ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer [J ] . Ann Oncol , 2021 , 32 ( 12 ): 1475 - 1495 . DOI: 10.1016/j.annonc.2021.09.019 http://doi.org/10.1016/j.annonc.2021.09.019

SI Y R , YUAN P , HU N L , et al . Primary tumor surgery for patients with de novo stage Ⅳ breast cancer can decrease local symptoms and improve quality of life [J ] . Ann Surg Oncol , 2020 , 27 ( 4 ): 1025 - 1033 . DOI: 10.1245/s10434-019-08092-2 http://doi.org/10.1245/s10434-019-08092-2

YU Y F , HONG H M , WANG Y , et al . Clinical evidence for locoregional surgery of the primary tumor in patients with de novo stage Ⅳ breast cancer [J ] . Ann Surg Oncol , 2021 , 28 ( 9 ): 5059 - 5070 . DOI: 10.1245/s10434-021-09650-3 http://doi.org/10.1245/s10434-021-09650-3

KHAN S A , ZHAO F M , GOLDSTEIN L J , et al . Early local therapy for the primary site in de novo stage Ⅳ breast cancer: results of a randomized clinical trial (EA2108) [J ] . J Clin Oncol , 2022 , 40 ( 9 ): 978 - 987 . DOI: 10.1200/JCO.21.02006 http://doi.org/10.1200/JCO.21.02006 https://ascopubs.org/doi/10.1200/JCO.21.02006 https://ascopubs.org/doi/10.1200/JCO.21.02006

KHAN S A , STEWART A K , MORROW M . Does aggressive local therapy improve survival in metastatic breast cancer? [J ] . Surgery , 2002 , 132 ( 4 ): 620-6;discussion626.

BABIERA G V , RAO R , FENG L , et al . Effect of primary tumor extirpation in breast cancer patients who present with stage Ⅳ disease and an intact primary tumor [J ] . Ann Surg Oncol , 2006 , 13 ( 6 ): 776 - 782 . DOI: 10.1245/ASO.2006.03.033 http://doi.org/10.1245/ASO.2006.03.033 http://link.springer.com/10.1245/ASO.2006.03.033 http://link.springer.com/10.1245/ASO.2006.03.033

RAPITI E , VERKOOIJEN H M , VLASTOS G , et al . Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis [J ] . J Clin Oncol , 2006 , 24 ( 18 ): 2743 - 2749 . DOI: 10.1200/JCO.2005.04.2226 http://doi.org/10.1200/JCO.2005.04.2226

BAFFORD A C , BURSTEIN H J , BARKLEY C R , et al . Breast surgery in stage Ⅳ breast cancer: impact of staging and patient selection on overall survival [J ] . Breast Cancer Res Treat , 2009 , 115 ( 1 ): 7 - 12 . DOI: 10.1007/s10549-008-0101-7 http://doi.org/10.1007/s10549-008-0101-7 http://link.springer.com/10.1007/s10549-008-0101-7 http://link.springer.com/10.1007/s10549-008-0101-7

LANE W O , THOMAS S M , BLITZBLAU R C , et al . Surgical resection of the primary tumor in women with de novo stage Ⅳ breast cancer: contemporary practice patterns and survival analysis [J ] . Ann Surg , 2019 , 269 ( 3 ): 537 - 544 . DOI: 10.1097/SLA.0000000000002621 http://doi.org/10.1097/SLA.0000000000002621 https://journals.lww.com/00000658-201903000-00024 https://journals.lww.com/00000658-201903000-00024

SORAN A , OZMEN V , OZBAS S , et al . Primary surgery with systemic therapy in patients with de novo stage Ⅳ breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial [J ] . J Am Coll Surg , 2021 , 233 ( 6 ): 742 - 751 .e5. DOI: 10.1016/j.jamcollsurg.2021.08.686 http://doi.org/10.1016/j.jamcollsurg.2021.08.686 https://journals.lww.com/10.1016/j.jamcollsurg.2021.08.686 https://journals.lww.com/10.1016/j.jamcollsurg.2021.08.686

BADWE R , PARMAR V , HAWALDAR R , et al . Abstract S2-02: surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial [J ] . Cancer Res , 2013 , 73 ( 24_Supplement ): S2 - 2 .

BADWE R , HAWALDAR R , NAIR N , et al . Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial [J ] . Lancet Oncol , 2015 , 16 ( 13 ): 1380 - 1388 . DOI: 10.1016/S1470-2045(15)00135-7 http://doi.org/10.1016/S1470-2045(15)00135-7

KING T A , LYMAN J P , GONEN M , et al . Prognostic impact of 21-gene recurrence score in patients with stage Ⅳ breast cancer: TBCRC 013 [J ] . J Clin Oncol , 2016 , 34 ( 20 ): 2359 - 2365 . DOI: 10.1200/JCO.2015.63.1960 http://doi.org/10.1200/JCO.2015.63.1960 https://ascopubs.org/doi/10.1200/JCO.2015.63.1960 https://ascopubs.org/doi/10.1200/JCO.2015.63.1960

RAO R , FENG L , KUERER H M , et al . Timing of surgical intervention for the intact primary in stage Ⅳ breast cancer patients [J ] . Ann Surg Oncol , 2008 , 15 ( 6 ): 1696 - 1702 . DOI: 10.1245/s10434-008-9830-4 http://doi.org/10.1245/s10434-008-9830-4 http://link.springer.com/10.1245/s10434-008-9830-4 http://link.springer.com/10.1245/s10434-008-9830-4

ZHU S Y . Exploring the value of additional primary tumour excision combined with systemic therapy administered in different sequences for patients with de novo metastatic breast cancer [J ] . Breast J , 2022 , 2022 : 5049445 .

KOMMALAPATI A , TELLA S H , GOYAL G , et al . A prognostic scoring model for survival after locoregional therapy in de novo stage Ⅳ breast cancer [J ] . Breast Cancer Res Treat , 2018 , 170 ( 3 ): 677 - 685 . DOI: 10.1007/s10549-018-4802-2 http://doi.org/10.1007/s10549-018-4802-2

GERA R , CHEHADE H E L H , WAZIR U , et al . Locoregional therapy of the primary tumour in de novo stage Ⅳ breast cancer in 216 066 patients: a meta-analysis [J ] . Sci Rep , 2020 , 10 ( 1 ): 2952 . DOI: 10.1038/s41598-020-59908-1 http://doi.org/10.1038/s41598-020-59908-1

POCKAJ B A , WASIF N , DUECK A C , et al . Metastasectomy and surgical resection of the primary tumor in patients with stage Ⅳ breast cancer: time for a second look? [J ] . Ann Surg Oncol , 2010 , 17 ( 9 ): 2419 - 2426 . DOI: 10.1245/s10434-010-1016-1 http://doi.org/10.1245/s10434-010-1016-1 http://link.springer.com/10.1245/s10434-010-1016-1 http://link.springer.com/10.1245/s10434-010-1016-1

BILANI N , ELSON L , LIANG H , et al . Effect of surgery at primary and metastatic sites in patients with stage Ⅳ breast cancer [J ] . Clin Breast Cancer , 2021 , 21 ( 3 ): 170 - 180 . DOI: 10.1016/j.clbc.2020.08.008 http://doi.org/10.1016/j.clbc.2020.08.008 https://linkinghub.elsevier.com/retrieve/pii/S1526820920302147 https://linkinghub.elsevier.com/retrieve/pii/S1526820920302147

BILANI N , YAGHI M , SINGH JABBAL I , et al . Survival benefit of a combined surgical approach in patients with metastatic breast cancer [J ] . J Surg Oncol , 2021 , 124 ( 8 ): 1235 - 1241 . DOI: 10.1002/jso.v124.8 http://doi.org/10.1002/jso.v124.8 https://onlinelibrary.wiley.com/toc/10969098/124/8 https://onlinelibrary.wiley.com/toc/10969098/124/8

HELLMAN S , WEICHSELBAUM R R . Oligometastases [J ] . J Clin Oncol , 1995 , 13 ( 1 ): 8 - 10 . DOI: 10.1200/JCO.1995.13.1.8 http://doi.org/10.1200/JCO.1995.13.1.8

CARDOSO F , PALUCH-SHIMON S , SENKUS E , et al . 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J ] . Ann Oncol , 2020 , 31 ( 12 ): 1623 - 1649 . DOI: 10.1016/j.annonc.2020.09.010 http://doi.org/10.1016/j.annonc.2020.09.010 https://linkinghub.elsevier.com/retrieve/pii/S0923753420424603 https://linkinghub.elsevier.com/retrieve/pii/S0923753420424603

LACAZE J L , AZIZA R , CHIRA C , et al . Diagnosis, biology and epidemiology of oligometastatic breast cancer [J ] . Breast , 2021 , 59 : 144 - 156 . DOI: 10.1016/j.breast.2021.06.010 http://doi.org/10.1016/j.breast.2021.06.010 https://linkinghub.elsevier.com/retrieve/pii/S0960977621004069 https://linkinghub.elsevier.com/retrieve/pii/S0960977621004069

BILANI N , YAGHI M , MAIN O , et al . Metastasectomy versus radiation of secondary sites in stage Ⅳ breast cancer: analysis from a national cancer registry [J ] . Breast , 2021 , 60 : 185 - 191 . DOI: 10.1016/j.breast.2021.10.005 http://doi.org/10.1016/j.breast.2021.10.005 https://linkinghub.elsevier.com/retrieve/pii/S0960977621009759 https://linkinghub.elsevier.com/retrieve/pii/S0960977621009759

IMOTO S , WANG K , BI X W , et al . Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1) [J ] . Breast Cancer , 2023 , 30 ( 3 ): 412 - 423 . DOI: 10.1007/s12282-023-01436-7 http://doi.org/10.1007/s12282-023-01436-7

SADOT E , LEE S Y , SOFOCLEOUS C T , et al . Hepatic resection or ablation for isolated breast cancer liver metastasis: a case-control study with comparison to medically treated patients [J ] . Ann Surg , 2016 , 264 ( 1 ): 147 - 154 . DOI: 10.1097/SLA.0000000000001371 http://doi.org/10.1097/SLA.0000000000001371

CHMURA S J , WINTER K A , WOODWARD W A , et al . NRG-BR002: a phase ⅡR/Ⅲ trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557) [J ] . J Clin Oncol , 2022 , 40 : 1007 . DOI: 10.1200/JCO.2022.40.16_suppl.1007 http://doi.org/10.1200/JCO.2022.40.16_suppl.1007 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.1007 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.1007

ZHENG C , YU Z G , CHINESE SOCIETY OF BREAST SURGERY . Clinical practice guidelines for pre-operative evaluation of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021 [J ] . Chin Med J (Engl) , 2021 , 134 ( 18 ): 2147 - 2149 .

Views

2533

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring innovative models of surgical treatment for rectal cancer

Influencing factors of cardiovascular adverse events risk in elderly patients with esophageal cancer undergoing video-assisted thoracoscopic surgery and nomogram prediction model construction

Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients

A case of rectal stromal tumor resection by da Vinci robotic surgery without an assisted abdominal incision

Diagnosis and management of giant cell tumor of bone in the spine: a brief review

Related Author

Dakui LUO

Xinxiang LI

Minghua CHEN

Bang ZENG

Xuehu TANG

Feng LI

Yiqun CAO

Changshuai ZHOU

Related Institution

Department of Colorectal Surgery, DivisionⅡ, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Anesthesiology, The First Hospital of Danjiangkou City

Department of General Thoracic Surgery, The First Hospital of Danjiangkou City

Department of Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Neurosurgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰

The value of surgery in the patients with de novo stage Ⅳ breast cancer

DOI：10.19401/j.cnki.1007-3639.2023.05.002

摘要

Abstract

关键词

Keywords

references